6533b858fe1ef96bd12b5b74
RESEARCH PRODUCT
Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins.
Ulrike KrahnJohannes J. LeschikYunsheng LiTanja DianaJochem KönigMichael KanitzPaul D. OlivoGeorge J. Kahalysubject
AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesSerial dilutionGraves' diseaseCHO CellsThyrotropin receptorYoung AdultCricetulusAntithyroid AgentsLimit of DetectionInternal medicineCricetinaemedicineBioassayAnimalsHumansProspective StudiesAgedDetection limitbiologyDose-Response Relationship DrugChemistryReproducibility of ResultsGeneral MedicineMiddle Agedmedicine.diseaseeye diseasesGraves DiseaseTiterEndocrinologybiology.proteinThyroid Stimulating ImmunoglobulinBiological AssayFemaleAntibodyBiomarkersImmunoglobulins Thyroid-Stimulatingdescription
Abstract The analytical performance and the clinical utility of a thyrotropin receptor (TSHR)–stimulating immunoglobulin (TSI) bioassay were compared with those of a TSHR-binding inhibitory immunoglobulin (TBII) assay. Limits of detection (LoD) and quantitation (LoQ), assay cutoff, and the half-maximal effective concentration (EC50) were measured. Dilution analysis was performed in sera of hyperthyroid patients with Graves disease (GD) during antithyroid treatment (ATD). Titer was defined as the first dilution step at which measurement of TSI or TBII fell below the assay cutoff. The LoD, LoQ, cutoff, and EC50 of the bioassay were 251-, 298-, 814-, and 827-fold lower than for the TBII assay. There were 22%, 42%, 23%, and 14% more positive samples in the TSI bioassay at dilutions of 1:3, 1:9, 1:27, and 1:81 (P < .0001), respectively. Responders to ATD demonstrated marked differences in titers compared with nonresponders. The bioassay detected lower levels of TSHR autoantibodies, and the dilution analysis provided similar predictive values of both assays in GD.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-02-01 | American journal of clinical pathology |